Urinary Incontinence Associated with Sertraline use in a Young SSRI-Naí¯ve Female Patient: a Case Report
Downloads
Introductions: Urinary incontinence is a side effect of several antidepressants, especially those in the SSRI and SNRI groups. Sertraline, a popular SSRI effective against a wide range of mental disorders, is one such drug with a clear association with a new onset of UI. Case: A 20-year-old Indonesian Chinese woman, presenting with mixed anxiety and depressive symptoms, was initially treated with sertraline 50 mg. She experienced an acute onset of urinary urgency and a loss of bladder control. These symptoms resolved upon discontinuation of sertraline. She was then given 10 mg of fluoxetine, and she noted that the urinary problems did not return. The medication was gradually tapered up to 40 mg/day with no remarkable adverse events. Discussions: Sertraline tends to stimulate micturition through effects on M3 muscarinic receptors on the bladder's detrusor muscle and inhibition of the dopamine transporter in the central nervous system. On the other hand, fluoxetine acts antagonistically on 5-HT2C, inhibiting the voiding reflex and promoting urinary continence. Therefore, though both are SSRIs, sertraline and fluoxetine may exhibit different, clinically meaningful effects. Conclusions: Clinicians need to have a greater awareness of urinary incontinence as a side effect of sertraline, as it impacts patients' adherence and quality of life. When possible, switching to fluoxetine is recommended for patients with urinary problems in the event of sertraline use.
Copyright (c) 2024 Anna Elissa
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
1. Copyright of this journal is possession of the Author, by the knowledge of the Editorial Board and Journal Manager, while the moral right of the publication belongs to the author.
2. The journal allows the author(s) to retain publishing rights without restrictions.
3. The articles are published under a Creative Commons Attribution Share-Alike (CC BY-SA) license. Many research funding bodies prefer the CC BY-SA license because it allows for maximum dissemination and re-use of open access materials. Users are free to share (copy, distribute, and transmit) and remix (adapt) the contribution under this license, including for commercial purposes, as long as they attribute the contribution in the manner specified by the author or licensor.